Liraglutide 3.0 Mg Improves Body Weight and Cardiometabolic Risk Factors in Overweight or Obese Adults without Diabetes: The Scale Obesity and Prediabetes Randomized, Double-Blind, Placebo-Controlled 56-Week Trial

被引：0
|
作者：
Le Roux, Carel [1 ]
Astrup, Arne [2 ]
Fujioka, Ken [3 ]
Greenway, Frank Lyons [4 ]
Halpern, Alfredo [5 ]
Krempf, Michel [6 ]
Lau, David C. [7 ]
Ortiz, Rafael Violante [8 ]
Wilding, John [9 ]
Jensen, Christine Bjorn [10 ]
Pi-Sunyer, F. Xavier [11 ]
机构：
[1] Univ Coll Dublin, Dublin, Ireland
[2] Univ Copenhagen, Frederiksberg C, Denmark
[3] Scripps Clin, La Jolla, CA 92037 USA
[4] Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA
[5] Univ Sao Paulo, Sao Paulo, Brazil
[6] Hop Nord Laennec, Nantes, France
[7] Univ Calgary, Calgary, AB, Canada
[8] Inst Mexicano Seguro Social, Cuidad Madero, Tamaulipas, Mexico
[9] Univ Liverpool, Liverpool, Merseyside, England
[10] Novo Nordisk AS, Soborg, Norway
[11] St Lukes Roosevelt Hosp, New York, NY 10025 USA
来源：
ENDOCRINE REVIEWS | 2014年 / 35卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT-0937
引用
收藏
页数：3
相关论文
共 50 条
  • [11] Liraglutide 3.0mg results in significant weight loss and improvements in cardiometabolic risk factors compared with liraglutide 1.8mg or placebo: a randomised, double-blind, 56 week trial in overweight/obese adults with Type 2 diabetes (SCALE diabetes)
    Davies, M. J.
    DeFronzo, R. A.
    Bergenstal, R. M.
    Bode, B. W.
    Kushner, R.
    Noctor, M.
    Jensen, T.
    Lewin, A.
    DIABETIC MEDICINE, 2015, 32 : 72 - 72
  • [12] Liraglutide 3.0 mg improves insulin secretion and action in overweight/obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial
    Lau, D. C. W.
    Wilding, J. P. H.
    Astrup, A.
    Fujioka, K.
    Greenway, F.
    Halpern, A.
    Krempf, M.
    le Roux, C.
    Violante Ortiz, R.
    Overgaard, R. V.
    Jensen, C. B.
    Pi-Sunyer, X.
    DIABETOLOGIA, 2014, 57 : S358 - S358
  • [13] Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial
    Fujioka, K.
    Wilding, J. P. H.
    Astrup, A.
    Greenway, F.
    Halpern, A.
    Krempf, M.
    Lau, D. C. W.
    le Roux, C.
    Violante Ortiz, R.
    Jensen, C. B.
    Lillleore, S. K.
    Pi-Sunyer, X.
    DIABETOLOGIA, 2014, 57 : S368 - S369
  • [14] Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial
    Pi-Sunyer, X.
    Fujioka, K.
    le Roux, C.
    Astrup, A.
    Greenway, F.
    Halpern, A.
    Krempf, M.
    Lau, D. C. W.
    Ortiz, R. Violante
    Jensen, C. B.
    Lillleore, S. K.
    Wilding, J. P. H.
    DIABETOLOGIA, 2014, 57 : S37 - S37
  • [15] Liraglutide Improves Weight Maintenance and Weight Loss in Obese Adults Without Diabetes After Diet-Induced Weight Loss: The SCALE™ 56-week Randomized Study
    Aronne, Louis J.
    Klein, Samuel
    Niswender, Kevin
    Hollander, Priscilla
    Woo, Vincent
    Hale, Paula M.
    Tu Duyen Le Thi
    Wadden, Thomas A.
    OBESITY, 2011, 19 : S177 - S177
  • [16] Effects of Liraglutide 3.0 mg Cessation on Efficacy and Safety/Tolerability Following a 56-Week Randomized Treatment Period in Obese/Overweight Adults with Type 2 Diabetes (SCALE™ Diabetes)
    Defronzo, Ralph A.
    Bode, Bruce W.
    Kushner, Robert F.
    Lewin, Andrew J.
    Skjoth, Trine V.
    Jensen, Christine B.
    Davies, Melanie
    DIABETES, 2014, 63 : A518 - A519
  • [17] Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: A six-month, randomized, placebo-controlled, double-blind clinical trial
    Tuccinardi, Dario
    Farr, Olivia M.
    Upadhyay, Jagriti
    Oussaada, Sabrina M.
    Mathew, Hannah
    Paschou, Stavroula A.
    Perakakis, Nikolaos
    Koniaris, Anastasia
    Kelesidis, Theodoros
    Mantzoros, Christos S.
    DIABETES OBESITY & METABOLISM, 2019, 21 (06): : 1487 - 1492
  • [18] Efficacy of noiiglutide injection on body weight in obese Chinese adults without diabetes: A multicentre, randomized, double-blind, placebo-controlled, phase 2 trial
    Li, Yijun
    Cheng, Zhifeng
    Lu, Weiping
    Li, Ping
    Jiang, Hongwei
    Yang, Jing
    Xu, Jing
    Zhang, Cheng
    Zhang, Lili
    Wang, Yao
    Bian, Fang
    Guo, Weiying
    Yu, Xuefeng
    Chen, Xiaopan
    Zhao, Dong
    Feng, Bo
    Qu, Shen
    Qin, Jie
    Zhang, Yifei
    Wang, Lin
    Cheng, Hong
    Mu, Yiming
    DIABETES OBESITY & METABOLISM, 2024, 26 (03): : 1057 - 1068
  • [19] Efficacy and Safety of Sinetrol-XPur on Weight and Body Fat Reduction in Overweight or Obese Adults: A 12-Week, Randomized, Double-Blind, Parallel, Placebo-Controlled Trial
    Park, Seon-Joo
    Sharma, Anshul
    Bae, Mun Hyoung
    Sung, Ha Chang
    Kim, Nam Ki
    Sung, Eunju
    Lee, Hae-Jeung
    JOURNAL OF MEDICINAL FOOD, 2020, 23 (03) : 335 - 342
  • [20] Effects of neoagarooligosaccharides on body fat and bowel movement indicators in overweight or obese adults: A randomized, double-blind, placebo-controlled trial
    Kim, Yeounhee
    Jung, Soyoung
    Cho, Seong Ah
    Lee, Je Hyeon
    Kim, Eun Joo
    Ko, Hye-Jeong
    Park, Yoo Kyoung
    JOURNAL OF FUNCTIONAL FOODS, 2024, 121
12345